פרופ' טיארי פקון - Prof. Thierry Facon

פרופ' טיארי פקון - Prof. Thierry Facon

Amen Israel -עמותת אמן - מיאלומה נפוצה

Algorithm for elderly patients | Thierry Facon

Tetsuzan Benny Ron

COMy 2016 Treatment of the Elderly: Facon

Tetsuzan Benny Ron

Thierry Facon: D-Rd vs. Rd in NDMM Ineligible for Transplant (MAIA)

EHA2024 |The IMROZ study

Myeloma Patients Europe

Thierry Facon, Centre Hospitalier Régional Universitaire de Lille, Lille, France

Dr Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed Myeloma

IACH 2019 Live - Management of elderly myeloma 30 years of active research

International Academy for Clinical Hematology IACH

IMROZ- IsaRVd vs RVd in Newly Diagnosed Transplant Ineligible MM | Thierry Facon, MD | EHA 2024

HealthTree Foundation for Multiple Myeloma

Quadruplet regimens and antibodies for newly diagnosed multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant...

IMROZ: Isa-VRd vs VRd for transplant-ineligible newly diagnosed multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma

Frontline treatment of elderly multiple myeloma patients and management of relapse/refractory

VJHemOnc – Video Journal of Hematology & HemOnc

Daratunumab found to increase PFS in patients with transplant-ineligible newly diagnosed multipl...

Immune Therapy

Institute for Myeloma & Bone Cancer Research, IMBCR

FIRST trial: Continuous lenalidomide plus dexamethasone for newly diagnosed multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Daratumumab increases PFS in patients with transplant-ineligible multiple myeloma

The Spleen

The Human Protein Atlas

Monoclonal antibodies for the treatment of multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc